Bryan Alzheimer's Disease Drug Discovery Program

Therapeutic Approaches: Small Molecules, Biomarkers

Therapeutic Areas of Expertise: Neurological Disorders, Psychiatric Disorders

Center/Program Highlights:

Collaborating in the Zinfandel-Takeda Alliance for a Phase III Pharmacogenetic-Assisted Trial of low-dose Pioglitazone for the delay and/or prevention of Mild Cognitive Impairment of the Alzheimer type. Member are consultants on the Joint Steering Committee, Joint Development Committee, Joint Biomarker Committee, and the Joint Patent Committee

Sources of Funding: Philanthropy, Industry Partnerships, Disease Foundations, Federal/State,

Industrial Partnerships: Zinfandel Pharmaceuticals, Inc., Takeda Pharmaceuticals, Inc


Institutional Affiliation(s): Duke University Bryan Alzheimer's Disease Research Center

R David Thomas Center
One Science Drive, Suite 342
North Carolina, 27708
United States

Center/Program Start Date: 2008

Number of Employees: 6